The cost–effectiveness of clopidogrel: a review by indication

References

• Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation100(15), 1667–1672 (1999).
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet348 1329–1339 (1996).
   Google Scholar
• Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345(7), 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Schleinitz MD, Olkin I, Heidenreich PA. Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials. Am. Heart J.148(6), 990–997 (2004).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA288(19), 2411–2420 (2002).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet358(9281), 527–533 (2001).
   PubMed Web of Science ®Google Scholar
• Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann. Intern. Med.128(7), 541–544 (1998).
   PubMed Web of Science ®Google Scholar
• Bennett CL, Davidson CJ, Raisch DW et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch. Intern. Med.159(21), 2524–2528 (1999).
   PubMed Web of Science ®Google Scholar
• Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Saf.19(2), 89–98 (1998).
   PubMed Web of Science ®Google Scholar
• Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet1(8649), 1215–1220 (1989).
   Google Scholar
• Hass WK, Easton JD, Adams HP Jr et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N. Engl. J. Med.321(8), 501–507 (1989).
   PubMed Web of Science ®Google Scholar
• Mizushima M, Iwata N, Fujimoto TT, Ishikawa K, Fujimura K. Patient characteristics in ticlopidine hydrochloride-induced liver injury: case-control study. Hepatol. Res. (2005).
   PubMedGoogle Scholar
• Bennett CL, Connors JM, Carwile JM et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N. Engl. J. Med.342(24), 1773–1777 (2000).
   PubMed Web of Science ®Google Scholar
• Zakarija A, Bandarenko N, Pandey DK et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke35(2), 533–537 (2004).
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC. In: Cost–Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
   Google Scholar
• Torrance GW, Siegel JE, Luce BR. In: Cost–Effectiveness in Health and Medicine. Weinstein MC (Ed.). Oxford University Press, NY, USA, 54–81 (1996).
   Google Scholar
• Luce RR, Manning WG, Siegel JE, Lipscomb J. In: Cost–Effectiveness in Health and Medicine. Weinstein MC (Ed.). Oxford University Press, NY, USA, 176–213 (1996).
   Google Scholar
• Lipscomb J, Weinstein MC, Torrance GW. In: Cost–Effectiveness in Health and Medicine. Weinstein MC (Ed.). Oxford University Press, NY, USA, 214–246 (1996).
   Google Scholar
• Peeters A, Mamun AA, Willekens F, Bonneux L. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur. Heart J.23(6), 458–466 (2002).
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost–effectiveness analyses: a case study in atherothrombosis. Value Health.7(5), 627–635 (2004).
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA, Beck JR. Markov Models in medical decision making: a practical guide. Med. Decis. Making.13(4), 322–338 (1993).
   PubMed Web of Science ®Google Scholar
• Jones L, Griffin S, Palmer S et al. Clinical effectiveness and cost–effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol. Assess.8(38), iii–iv, 1–196 (2004).
   Web of Science ®Google Scholar
• Gaspoz JM, Coxson PG, Goldman PA et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N. Engl. J. Med.346(23), 1800–1806 (2002).
   PubMed Web of Science ®Google Scholar
• Oxman AD, Guyatt GH. A consumer’s guide to subgroup analyses. Ann. Intern. Med.116(1), 78–84 (1992).
   PubMed Web of Science ®Google Scholar
• Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am. J. Med.116(12), 797–806 (2004).
   PubMed Web of Science ®Google Scholar
• Matchar DB, Samsa GP, Liu S. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty. Value Health.8(5), 572–580 (2005).
   PubMed Web of Science ®Google Scholar
• Sarasin FP, Gaspoz JM, Bounameaux H. Cost–effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch. Intern. Med.160(18), 2773–2778 (2000).
   PubMedGoogle Scholar
• Karnon J, Brennan A, Pandor A et al. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Curr. Med. Res. Opin.21(1), 101–112 (2005).
   PubMed Web of Science ®Google Scholar
• Annemans L, Lamotte M, Levy E, Lenne X. Cost–effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial. J. Med. Econ.6,55–68 (2003).
   Google Scholar
• Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.J. Neurol. Sci.143(1–2), 1–13 (1996).
   PubMed Web of Science ®Google Scholar
• Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke22(3), 312–318 (1991).
   PubMed Web of Science ®Google Scholar
• Schleinitz MD. Cost–effectiveness of antiplatelet therapies. Arch. Intern. Med.161(9), 1236 (2001).
   PubMedGoogle Scholar
• Yusuf S, Mehta SR, Zhao F et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation107(7), 966–972 (2003).
   PubMed Web of Science ®Google Scholar
• Lindgren P, Jonsson B, Yusuf S. Cost–effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial. J. Intern. Med.255(5), 562–570 (2004).
   PubMed Web of Science ®Google Scholar
• Latour-Perez J, Navarro-Ruiz A, Ridao-Lopez M, Cervera-Montes M. Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost–utility analysis in Spain. Value Health.7(1), 52–60 (2004).
   PubMed Web of Science ®Google Scholar
• Main C, Palmer S, Griffin S et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol. Assess.8(40), iii–iv, xv–xvi, 1–141 (2004).
   Google Scholar
• Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann. Intern. Med.142(4), 251–259 (2005).
   PubMed Web of Science ®Google Scholar
• Weintraub WS, Mahoney EM, Lamy A et al. Long-term cost–effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J. Am. Coll. Cardiol.45(6), 838–845 (2005).
   PubMed Web of Science ®Google Scholar
• Karnon J, Bakhai A, Brennan A et al. A cost–utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK. Int. J. Cardiol.(2005) (In Press).
   PubMedGoogle Scholar
• Mahoney EM, Mehta S, Yuan Y et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am. Heart J.151(1), 219–227 (2006).
   PubMed Web of Science ®Google Scholar
• Lindgren P, Stenestrand U, Malmberg K, Jonsson B. The long-term cost–effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clin. Ther.27(1), 100–110 (2005).
   PubMed Web of Science ®Google Scholar
• Beinart SC, Kolm P, Veledar E et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J. Am. Coll. Cardiol.46(5), 761–769 (2005).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA294(10), 1224–1232 (2005).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med.352(12), 1179–1189 (2005).
   PubMed Web of Science ®Google Scholar
• Bhatt DL,Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am. Heart J.148(2), 263–268 (2004).
   PubMed Web of Science ®Google Scholar
• Kulik A, Le May M, Wells GA, Mesana TG, Ruel M. The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. Curr. Control Trials Cardiovasc. Med.6(1), 15 (2005).
   PubMedGoogle Scholar
• Cohen DJ, Bakhai A, Shi C et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation110(5), 508–514 (2004).
   PubMed Web of Science ®Google Scholar